Wealthfront Advisers LLC Reduces Stake in Astrazeneca Plc $AZN

Wealthfront Advisers LLC cut its stake in shares of Astrazeneca Plc (NYSE:AZN) by 74.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,171 shares of the company’s stock after selling 3,415 shares during the period. Wealthfront Advisers LLC’s holdings in Astrazeneca were worth $231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Triumph Capital Management purchased a new position in Astrazeneca during the third quarter worth $25,000. MV Capital Management Inc. purchased a new stake in shares of Astrazeneca in the fourth quarter valued at $26,000. Mascoma Wealth Management LLC purchased a new stake in shares of Astrazeneca in the first quarter valued at $26,000. Bangor Savings Bank lifted its holdings in shares of Astrazeneca by 102.7% in the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC bought a new stake in shares of Astrazeneca in the 4th quarter worth about $30,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

AZN opened at $168.41 on Friday. The company has a market capitalization of $261.19 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 1.38 and a beta of 0.24. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12-month low of $142.98 and a 12-month high of $212.71. The business’s fifty day simple moving average is $180.80 and its 200-day simple moving average is $188.05.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. On average, equities research analysts anticipate that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the topic of several analyst reports. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. UBS Group restated a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. HSBC cut Astrazeneca from a “buy” rating to a “hold” rating in a research note on Monday, July 13th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.